The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study - 11/02/19
Abstract |
Background |
Repigmentation at previous biopsy sites pose a significant diagnostic dilemma given clinical and histologic similarities between recurrent nevi and locally recurrent melanoma. Though common in melanoma, the role of TERT promoter mutations (TPMs) in recurrent nevi is unknown.
Objective |
We investigated the role of TPMs in recurrent nevi and whether the presence of hotspot TPM distinguishes recurrent nevi from locally recurrent melanoma. We also characterized clinical and histologic features differentiating these lesions.
Methods |
We analyzed 11 locally recurrent melanomas, 17 recurrent nevi, and melanoma and nevus controls to determine TPM status. We also assessed clinical and histologic features of the recurrent groups.
Results |
Hotspot TPMs were more common in recurrent melanomas than recurrent nevi (P = .008). Recurrent melanomas were more likely to have solar elastosis (P = .0047), multilayering of melanocytes in the epidermis (P = .0221), adnexal involvement (P = .0069), and epidermal consumption (P = .0204). Recurrent nevi had intra-epidermal atypia limited to the area above the scar (P < .0001) and occurred earlier after the original biopsy (P < .0008). Solar elastosis, months to recurrence, and hotspot TPMs were independently associated with recurrent melanoma in multivariate analysis.
Limitations |
This was a retrospective study.
Conclusion |
Hotspot TPMs are significantly more frequent in recurrent melanomas and could serve as a diagnostic clue in histologically ambiguous cases.
Le texte complet de cet article est disponible en PDF.Key words : borderline lesions, locally recurrent melanoma, melanoma in scar, recurrent nevi, regenerating nevus, repigmentation within a scar, TERT, TERT promoter mutation, TPM
Abbreviations used : DEJ, TERT, TPM
Plan
| Dr Walton and Ms Garfield contributed equally to this article. |
|
| Funding sources: Supported by the IDP Foundation Inc. |
|
| Conflicts of interest: Dr Gerami has served as a consultant for DermTech and Castle Biosciences and has received honoraria for this. All other authors have no conflicts of interest to disclose. |
Vol 80 - N° 3
P. 685-693 - mars 2019 Retour au numéro
Article précédent
- Bundled payment for actinic keratosis management: Pilot evaluation of developed models
- Joslyn S. Kirby, Colleen F. Silva, Sara B. Ferguson, David Shupp, James G. Marks, Jeffrey J. Miller
- Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels
- Bruno L. Rodrigues, Silmara A.L. Montalvão, Rebeca B.B. Cancela, Francesca A.R. Silva, Aline Urban, Stephany C. Huber, José Luiz R.C. Júnior, José Fábio S.D. Lana, Joyce M. Annichinno-Bizzacchi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?